Meanwhile Jim Xu from Bristol Myers Squibb talks upstream process dev "at pandemic speed" in the cell culture track here at #biotechweekboston ... it's good to be back!

Two co-founders of Taiwanese firm JHL Biotech were sentenced last month for plotting to steal trade secrets from Genentech and commit wire fraud exceeding $101 million. @BiProInsider spoke to the attorneys who represented #Genentec…lnkd.in/euNX3HPD lnkd.in/ehDqu_Xi

A win for CDMO Catalent as it further strengthens its global network, but potentially a loss to the UK taxpayer, which helped fund the $260 million Vaccine Manufacturing & Innovation Centre (VMIC) lnkd.in/ef4YmHG9

The US Department of Health and Human Services #HHS has terminated a long-term #CDMO partnership with Emergent BioSolutions, which included a $628 million deal to produce #COVID19 vaccines. lnkd.in/eaY7E6yx

At the prestigious #CPhIWorldwide awards ceremony drinking wine from a paper cup

In the latest example of pandemic-related collaboration, @Novartis is prepping to make the drug substance for Roche’s Actemra (tocilizumab), currently being investigated as a treatment for severe #COVID19 -associated pneumonia buff.ly/3tnZLkH

As part of a “difficult decision” to halt its biosimilars programs in China, Pfizer is offloading its single-use biologics manufacturing plant in Hangzhou to #CDMO WuXi Biologics shar.es/aoIkk8

Thermo Fisher’s $600 million CAPEX has got the trade press salivating. But similar statements, expansions underway, and continued demand mean this is just another day in the pandemic-fueled bioprocess space buff.ly/3l5Z7VE

Calls for standardization to boost manufacturing agility by executives from Novavax, Fujifilm, and Biocon after a Cytiva-led survey showed flexibility is a major priority for biopharma buff.ly/3r7hVpN

Merck & Co. will add a pipeline of precision immune modulators and a drug design and discovery platform through the proposed acquisition of Pandion Therapeutics lnkd.in/emYHFg7

$CRL Charles River to reenter #CDMO space in $875m Cognate buy - Deal adds autologous and allogeneic #celltherapy, plasmid DNA and viral vector manufacturing capabilities buff.ly/3dq5VvM

Pfizer expects to cut COVID-19 vaccine production time by close to 50% as production ramps up, efficiencies increase usatoday.com/story/news/heal… via @usatoday

While #CDMOs continue to expand biologics and advanced therapy services recent divestments from @Lonza and @Catalent do not indicate the abandonment of small molecules capabilities buff.ly/3pw8zD8

Moderna says it has capacity to deliver 1 billion doses of its mRNA COVID-19 vaccine but with raw materials in high demand can it guarantee the supply? #JPM2021 Story from @BioProInsider buff.ly/3oMQLUe

CureVac has hired Bayer to help develop mRNA-based medicines including the COVID-19 vaccine candidate, CVnCoV. Bayer joins Wacker and Fareva. lnkd.in/eehMMgA